Pharmaceuticals

Huadong Medicine Announces Positive Preliminary Results from a Phase Ⅰ study of HDM2005, a ROR1-Targeting ADC

 HANGZHOU, China, Sept. 5, 2025 /PRNewswire/ -- Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") today announced positive preliminary results from a Phase I study of HDM2005, an independently developed Class 1 innovative?antibody–drug conjugate (ADC) targeting receptor ty...

2025-09-05 21:38 1893

FUTUONING Sets Sail Commercially with First Prescriptions Across China

 SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- These days, the first prescriptions of FUTUONING (fovinaciclib citrate capsules) were issued by more than ten hospitals acrossChina, including Fudan University Shanghai Cancer Center, Cancer Hospital of the Chinese Academy of Medical Sciences, The First Af...

2025-09-05 18:12 987

Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

 LEHI, Utah, Sept. 4, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced that the Company plans to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. Jared Bearss...

2025-09-04 20:00 984

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS? (denosumab-nxxp) and BILPREVDA? (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

 SHANGHAI and JERSEY CITY,?N.J., Sept. 2, 2025 /PRNewswire/ --?Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS? (denosumab-nxxp) injection 60 mg/mL and BILPREVDA? (denosumab-nxxp) injection 120 mg/1.7 ...

2025-09-02 21:10 1613

Seegene and Springer Nature Open Applications for 2025-2026 Nature Awards MDx Impact Grants

 -??????? The program focuses on antibiotic resistance in urinary tract infections (UTI-DR), with applications open untilNovember 20; final awardees to be announced inAugust 2026 -??????? Selected researchers will receive up to USD 600,000 in research funding, along with access to Seegene's syndro...

2025-09-02 21:00 1561

LOTTE BIOLOGICS establishes contract manufacturing partnership with a leading U.S. Biopharmaceutical Company

 Secures third contract this year, reinforcing global competitiveness?and expanding strategic partnerships SEOUL, South Korea and SYRACUSE, N.Y., Sept. 2, 2025 /PRNewswire/ -- LOTTE BIOLOGICS (CEOJames Park) today announced that it has entered a late-stage to commercial contract manufacturing par...

2025-09-02 08:00 804

Norma Completes Quantum AI Algorithm Validation on NVIDIA

 "Quantum AI up to 73x Faster on NVIDIA CUDA-Q" * Norma, a quantum computing company, has validated the performance of quantum AI algorithms using NVIDIA CUDA-Q. * By running these algorithms for drug development on CUDA-Q, Norma observed computational speeds up to 73 times faster. * The com...

2025-09-01 21:00 1260

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

 * 26 scientific abstracts, including two oral presentations, demonstrate?UCB's ongoing commitment to advancing research for people living with epilepsies * Data include an open-label extension study describing the long-term safety of?FINTEPLA?▼?(fenfluramine)[1] and global functioning in chil...

2025-08-29 14:00 1915

Everest Medicines Announces Interim Results for First Half of 2025

 SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025 a...

2025-08-29 07:52 2043

ACROBiosystems and DAAN Biotherapeutics Sign Strategic MOU for the Development of Precision Immuno-Oncology Therapeutics

 SEOUL, South Korea, Aug. 28, 2025 /PRNewswire/ -- ACROBiosystems, a global biotechnology company dedicated to accelerating the drug development process through innovative tools and solutions, announced that it has entered into a strategic Memorandum of Understanding (MOU) with DAAN Biotherapeutic...

2025-08-28 09:54 1086

AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector

 HONG KONG, Aug. 28, 2025 /PRNewswire/ --?AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are ...

2025-08-28 07:45 1018

Fosun International: Total Revenue for the First Half of 2025 Reaches RMB87.28 Billion, Industrial Operation Profit Amounts to RMB3.15 Billion

 HONG KONG, Aug. 27, 2025 /PRNewswire/ -- On 27 August, Fosun International Limited (HKEX stock code: 00656) announced its interim results for the six months ended30 June 2025. In the first half of 2025, Fosun actively captured macroeconomic trends, maintained a clear strategic focus, and leverag...

2025-08-27 20:40 2259

Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment

 * Abbott's?denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of Thais * This approval builds on Abbott's biosimilar portfolio in Asia Pacific, following recent launches inMalaysia and Indi...

2025-08-26 14:29 1384

Basecare Medical (02170.HK) Gems Culture Medium Receives First Approval from NMPA, Advancing the Localization of Assisted Reproductive Fluids

 SUZHOU, China, Aug. 26, 2025 /PRNewswire/ -- Recently,?Suzhou Basecare Medical Co., Ltd. achieved a major breakthrough—its globally leading Gems culture medium (embryo handling solution VitBase) has officially received registration approval from the National Medical Products Administration (NMPA)...

2025-08-26 11:47 1252

Neopharma Technologies and Orient Gene Partner to Digitize Healgen? Drug Test Portfolio Globally with NEOVAULT?

 Partnership delivers tamper-evident, high-integrity testing data aligned with U.S. Drug Policy Priorities WASHINGTON, Aug. 26, 2025 /PRNewswire/ -- Neopharma Technologies Limited ("Neopharma") today announced it hasentered into a global software licensing and collaboration agreement with Zhejian...

2025-08-26 02:10 1261

Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach

 SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390....

2025-08-25 21:18 2306

Everest Medicines Announces Participation in September Investor Conferences

 SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fin...

2025-08-25 20:57 1227

Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial

 NANJING, China, Aug. 25, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following strong Phase Ⅰ data.This milestone endows...

2025-08-25 18:27 1196

Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer

 SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment ofFrancis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and ...

2025-08-25 16:42 1276

Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy

 * The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1 * DEEs ar...

2025-08-25 15:43 905